Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
33 hedge funds and large institutions have $8.73M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 26 closing their positions.
686% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $279K
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
33% less funds holding
Funds holding: 49 → 33 (-16)
47% less capital invested
Capital invested by funds: $16.4M → $8.73M (-$7.66M)
62% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.56M |
| 2 |
Renaissance Technologies
New York
|
+$1.47M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.01M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$219K |
| 5 |
VF
Virtu Financial
New York
|
+$95.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.41M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$569K |
| 3 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
-$172K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$160K |
| 5 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
-$127K |
NBRV Hedge Fund Activity: Q4 2020 in Review
33 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q4 2020, worth a combined $8.73M — down 47% from $16.4M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of NBRV and 10 opened new positions — a net loss of 16 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Morgan Stanley, adding an estimated $1.56M. The largest seller was OrbiMed, exiting entirely with an estimated $1.41M sold.
- 33 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q4 2020, down from 49 in Q3 2020.
- Funds reported $8.73M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q4 2020, down 47% quarter-over-quarter.
- 10 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q4 2020 and 26 closed out, a net change of -16 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q4 2020 was Morgan Stanley, an estimated $1.56M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q4 2020 was OrbiMed, an estimated $1.41M sold.
Based on aggregated 13F filings for Q4 2020.